Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 25

1.

Comparable composite endpoints after HLA-matched and HLA-haploidentical transplantation with post-transplantation cyclophosphamide.

McCurdy SR, Kasamon YL, Kanakry CG, Bolaños-Meade J, Tsai HL, Showel MM, Kanakry JA, Symons HJ, Gojo I, Smith BD, Bettinotti MP, Matsui WH, Dezern AE, Huff CA, Borrello I, Pratz KW, Gladstone DE, Swinnen LJ, Brodsky RA, Levis MJ, Ambinder RF, Fuchs EJ, Rosner GL, Jones RJ, Luznik L.

Haematologica. 2017 Feb;102(2):391-400. doi: 10.3324/haematol.2016.144139. Epub 2016 Oct 20.

2.

Loss of the mismatched human leukocyte antigen haplotype in two acute myelogenous leukemia relapses after haploidentical bone marrow transplantation with post-transplantation cyclophosphamide.

McCurdy SR, Iglehart BS, Batista DA, Gocke CD, Ning Y, Knaus HA, Jackson AM, Leffell MS, Luznik L, Gojo I.

Leukemia. 2016 Oct;30(10):2102-2106. doi: 10.1038/leu.2016.144. Epub 2016 May 23. No abstract available.

3.

Histone deacetylase inhibitors decrease NHEJ both by acetylation of repair factors and trapping of PARP1 at DNA double-strand breaks in chromatin.

Robert C, Nagaria PK, Pawar N, Adewuyi A, Gojo I, Meyers DJ, Cole PA, Rassool FV.

Leuk Res. 2016 Jun;45:14-23. doi: 10.1016/j.leukres.2016.03.007. Epub 2016 Mar 30.

4.

Outcomes of Nonmyeloablative HLA-Haploidentical Blood or Marrow Transplantation With High-Dose Post-Transplantation Cyclophosphamide in Older Adults.

Kasamon YL, Bolaños-Meade J, Prince GT, Tsai HL, McCurdy SR, Kanakry JA, Rosner GL, Brodsky RA, Perica K, Smith BD, Gladstone DE, Swinnen LJ, Showel MM, Matsui WH, Huff CA, Borrello I, Pratz KW, McDevitt MA, Gojo I, Dezern AE, Shanbhag S, Levis MJ, Luznik L, Ambinder RF, Fuchs EJ, Jones RJ.

J Clin Oncol. 2015 Oct 1;33(28):3152-61. doi: 10.1200/JCO.2014.60.4777. Epub 2015 Aug 10.

5.

Randomized multicenter phase II study of flavopiridol (alvocidib), cytarabine, and mitoxantrone (FLAM) versus cytarabine/daunorubicin (7+3) in newly diagnosed acute myeloid leukemia.

Zeidner JF, Foster MC, Blackford AL, Litzow MR, Morris LE, Strickland SA, Lancet JE, Bose P, Levy MY, Tibes R, Gojo I, Gocke CD, Rosner GL, Little RF, Wright JJ, Doyle LA, Smith BD, Karp JE.

Haematologica. 2015 Sep;100(9):1172-9. doi: 10.3324/haematol.2015.125849. Epub 2015 May 28.

6.

Immunomodulatory Drugs: Immune Checkpoint Agents in Acute Leukemia.

Knaus HA, Kanakry CG, Luznik L, Gojo I.

Curr Drug Targets. 2017;18(3):315-331. doi: 10.2174/1389450116666150518095346.

7.

Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide.

McCurdy SR, Kanakry JA, Showel MM, Tsai HL, Bolaños-Meade J, Rosner GL, Kanakry CG, Perica K, Symons HJ, Brodsky RA, Gladstone DE, Huff CA, Pratz KW, Prince GT, Dezern AE, Gojo I, Matsui WH, Borrello I, McDevitt MA, Swinnen LJ, Smith BD, Levis MJ, Ambinder RF, Luznik L, Jones RJ, Fuchs EJ, Kasamon YL.

Blood. 2015 May 7;125(19):3024-31. doi: 10.1182/blood-2015-01-623991. Epub 2015 Mar 26.

8.

New strategies in acute myelogenous leukemia: leukemogenesis and personalized medicine.

Gojo I, Karp JE.

Clin Cancer Res. 2014 Dec 15;20(24):6233-41. doi: 10.1158/1078-0432.CCR-14-0900. Epub 2014 Oct 16. Review.

9.

Single-agent GVHD prophylaxis with posttransplantation cyclophosphamide after myeloablative, HLA-matched BMT for AML, ALL, and MDS.

Kanakry CG, Tsai HL, Bolaños-Meade J, Smith BD, Gojo I, Kanakry JA, Kasamon YL, Gladstone DE, Matsui W, Borrello I, Huff CA, Swinnen LJ, Powell JD, Pratz KW, DeZern AE, Showel MM, McDevitt MA, Brodsky RA, Levis MJ, Ambinder RF, Fuchs EJ, Rosner GL, Jones RJ, Luznik L.

Blood. 2014 Dec 11;124(25):3817-27. doi: 10.1182/blood-2014-07-587477. Epub 2014 Oct 14.

10.

Integrated analysis of CRLF2 signaling in acute lymphoblastic leukemia identifies Polo-like kinase 1 as a potential therapeutic target.

Huang TC, Cutler J, Bharne S, Zhong J, Weinstock D, Tyner J, Gojo I, Civin C, Pandey A.

Leuk Lymphoma. 2015 May;56(5):1524-7. doi: 10.3109/10428194.2014.963076. Epub 2014 Nov 5. No abstract available.

11.

A phase II trial of sequential ribonucleotide reductase inhibition in aggressive myeloproliferative neoplasms.

Zeidner JF, Karp JE, Blackford AL, Smith BD, Gojo I, Gore SD, Levis MJ, Carraway HE, Greer JM, Ivy SP, Pratz KW, McDevitt MA.

Haematologica. 2014 Apr;99(4):672-8. doi: 10.3324/haematol.2013.097246. Epub 2013 Dec 20.

12.

CHK1 and WEE1 inhibition combine synergistically to enhance therapeutic efficacy in acute myeloid leukemia ex vivo.

Chaudhuri L, Vincelette ND, Koh BD, Naylor RM, Flatten KS, Peterson KL, McNally A, Gojo I, Karp JE, Mesa RA, Sproat LO, Bogenberger JM, Kaufmann SH, Tibes R.

Haematologica. 2014 Apr;99(4):688-96. doi: 10.3324/haematol.2013.093187. Epub 2013 Oct 31.

13.

Clinical and laboratory studies of the novel cyclin-dependent kinase inhibitor dinaciclib (SCH 727965) in acute leukemias.

Gojo I, Sadowska M, Walker A, Feldman EJ, Iyer SP, Baer MR, Sausville EA, Lapidus RG, Zhang D, Zhu Y, Jou YM, Poon J, Small K, Bannerji R.

Cancer Chemother Pharmacol. 2013 Oct;72(4):897-908. doi: 10.1007/s00280-013-2249-z. Epub 2013 Aug 15.

14.

Thoracic t(9;22)-positive granulocytic sarcoma as initial presentation of chronic myeloid leukemia.

Mitchell M, Itani D, Gerber J, Ghosh N, Gojo I, Zeidan A.

Clin Lymphoma Myeloma Leuk. 2013 Oct;13(5):619-21. doi: 10.1016/j.clml.2013.04.012. Epub 2013 Jun 10. No abstract available.

15.

Cryptic chromosome abnormalities in a patient with mixed phenotype acute leukemia.

Ning Y, Slovak ML, Schultz RA, Gojo I, Baer MR.

Leuk Lymphoma. 2014 Mar;55(3):680-2. doi: 10.3109/10428194.2013.809076. Epub 2013 Jul 10. No abstract available.

16.

Phase I study of UCN-01 and perifosine in patients with relapsed and refractory acute leukemias and high-risk myelodysplastic syndrome.

Gojo I, Perl A, Luger S, Baer MR, Norsworthy KJ, Bauer KS, Tidwell M, Fleckinger S, Carroll M, Sausville EA.

Invest New Drugs. 2013 Oct;31(5):1217-27. doi: 10.1007/s10637-013-9937-8. Epub 2013 Feb 27.

17.

Translational phase I trial of vorinostat (suberoylanilide hydroxamic acid) combined with cytarabine and etoposide in patients with relapsed, refractory, or high-risk acute myeloid leukemia.

Gojo I, Tan M, Fang HB, Sadowska M, Lapidus R, Baer MR, Carrier F, Beumer JH, Anyang BN, Srivastava RK, Espinoza-Delgado I, Ross DD.

Clin Cancer Res. 2013 Apr 1;19(7):1838-51. doi: 10.1158/1078-0432.CCR-12-3165. Epub 2013 Feb 12.

18.

Targeting abnormal DNA double-strand break repair in tyrosine kinase inhibitor-resistant chronic myeloid leukemias.

Tobin LA, Robert C, Rapoport AP, Gojo I, Baer MR, Tomkinson AE, Rassool FV.

Oncogene. 2013 Apr 4;32(14):1784-93. doi: 10.1038/onc.2012.203. Epub 2012 May 28.

19.

Single cycle of arsenic trioxide-based consolidation chemotherapy spares anthracycline exposure in the primary management of acute promyelocytic leukemia.

Gore SD, Gojo I, Sekeres MA, Morris L, Devetten M, Jamieson K, Redner RL, Arceci R, Owoeye I, Dauses T, Schachter-Tokarz E, Gallagher RE.

J Clin Oncol. 2010 Feb 20;28(6):1047-53. doi: 10.1200/JCO.2009.25.5158. Epub 2010 Jan 19.

20.

Diagnosis of biphenotypic acute leukemia: a paradigmatic approach.

Zhao XF, Gojo I, York T, Ning Y, Baer MR.

Int J Clin Exp Pathol. 2009 Oct 10;3(1):75-86.

Supplemental Content

Loading ...
Support Center